Emerging strategies for high-risk and relapsed/refractory acute myeloid leukemia: Novel agents and approaches currently in clinical trials

Blood Reviews

Volumn 29, Issue 1, 2015, Pages 1-9

  Sasine, Joshua P ^a   Schiller, Gary J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bispecific T cell engaging antibodies; CPX 351; FLT3; Gemtuzumab ozogamicin; High risk AML; IDH; Midostaurin; Quizartinib; Sapacitabine; Sorafenib; Volasertib; Vosaroxin

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ASPARAGINASE; AZACITIDINE; BISMUTH 213; BORTEZOMIB; CD47 ANTIGEN; CYTARABINE; CYTARABINE PLUS DAUNORUBICIN; DAUNORUBICIN; DENDRITIC CELL VACCINE; ELACYTARABINE; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; LINTUZUMAB; MIDOSTAURIN; MITOXANTRONE; NANOPARTICLE; ORPHAN DRUG; PEPTIDE VACCINE; PLACEBO; PONATINIB; QUIZARTINIB; RETINOIC ACID; SAPACITABINE; SORAFENIB; VOLASERTIB; VOSAROXIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTERY THROMBOSIS; ARTICLE; BONE MARROW SUPPRESSION; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); CONTROLLED DRUG RELEASE; CYTOPENIA; DISEASE FREE SURVIVAL; DONOR LYMPHOCYTE INFUSION; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FEVER; GASTROINTESTINAL SYMPTOM; GRAFT VERSUS LEUKEMIA EFFECT; HAIR LOSS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFLAMMATORY INFILTRATE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LOW DRUG DOSE; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; OFF LABEL DRUG USE; OVERALL SURVIVAL; PNEUMONIA; PROMYELOCYTIC LEUKEMIA; UNSPECIFIED SIDE EFFECT; ANIMAL; IMMUNOTHERAPY; LEUKEMIA, MYELOID, ACUTE; PATHOLOGY; PROCEDURES; RECURRENT DISEASE;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; LEUKEMIA, MYELOID, ACUTE; MOLECULAR TARGETED THERAPY; RECURRENCE;

EID: 84921766467     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2014.07.002     Document Type: Article

References (94)

1. Patel J., Levine R. How do novel molecular genetic markers influence treatment decisions in acute myeloid leukemia?. Hematol Amazon Soc Hematol Educ Program 2012, 2012:28-34.
2. Marcucci G., Haferlach T., Dohner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 2011, 29(13):475-486.
3. Schiller G.J. High-risk acute myelogenous leukemia: treatment today and tomorrow. Hematol Am Soc Hematol Educ Program 2013, 2013:201-208.
4. Vardiman J.W., Thiele J., Arber D.A., Brunning R.D., Borowitz M.J., Porwit A., et al. The 2008 revision of the World Health Organization classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114(5):937-951.
5. Middeke J.M., Beelen D., Stadler M., Göhring G., Schlegelberger B., Baurmann H., et al. Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl(17p) and -5/5q- Blood 2012, 120(12):2521-2528.
6. Paietta E. Minimal residual disease in acute myeloid leukemia: coming of age. Hematol Am Soc Hematol Educ Program 2012, 2012:35-42.
7. Kantarjian H., Ravandi F., O'Brien S., Cortes J., Faderl S., Garcia-Manero G., et al. Intensive chemotherapy does not benefit most older patients (age 70years or older) with acute myeloid leukemia. Blood Nov 25 2010, 116(22):4422-4429.
8. Schiller G. When a gold standard is made of tin. Blood 2010, 116(22):4386-4387.
9. Keng M.K., Wenzell C.M., Sekeres M.A. A drug's life: the pathway to drug approval. Clin Adv Hematol Oncol Oct 2013, 11(10):646-655. [Review].
10. ODAC Briefing Document NDA022-489, p 9. Available from:. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM180496.pdf.
11. Schiller G.J. Allogeneic transplantation as therapy for acute myelogenous leukemia in the elderly. Biol Blood Marrow Transplant Apr 2014, 20(4):437-438.
12. Thiede C., Steudel C., Mohr B., Schaich M., Schäkel U., Platzbecker U., et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood Jun 15 2002, 99(12):4326-4335.
13. Abu-Duhier F.M., Goodeve A.C., Wilson G.A., Care R.S., Peake I.R., Reilly J.T. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol Jun 2001, 113(4):983-988.
14. Yamamoto Y., Kiyoi H., Nakano Y., Suzuki R., Kodera Y., Miyawaki S., et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood Apr 15 2001, 97(8):2434-2439.
15. Stone R.M., DeAngelo D.J., Klimek V., Galinsky I., Estey E., Nimer S.D., et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood Jan 1 2005, 105(1):54-60.
16. Knapper S., Burnett A.K., Littlewood T., Kell W.J., Agrawal S., Chopra R., et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood Nov 15 2006, 108(10):3262-3270.
17. Pratz K.W., Cortes J., Roboz G.J., Rao N., Arowojolu O., Stine A., et al. A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood Apr 23 2009, 113(17):3938-3946.
18. Serve H., Krug U., Wagner R., Sauerland M.C., Heinecke A., Brunnberg U., et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol Sep 1 2013, 31(25):3110-3118.
19. Ravandi F., Alattar M.L., Grunwald M.R., Rudek M.A., Rajkhowa T., Richie M.A., et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood Jun 6 2013, 121(23):4655-4662.
20. Man C.H., Fung T.K., Ho C., Han H.H., Chow H.C., Ma A.C., et al. Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. Blood May 31 2012, 119(22):5133-5143.
21. Cortes J.E., Perl A.E., Dombret H., Kayser S., Steffen B., Rousselot P., et al. Final results of a phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients ≥60years of age with FLT3 ITD positive or negative relapsed/refractory acute myeloid leukemia. ASH Annual Meeting Abstracts 2012, 120:48.
22. Levis M.J., Perl A.E., Dombret H., Döhner H., Steffen B., Rousselot P., et al. Final results of a phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia after second-line chemotherapy or hematopoietic stem cell transplantation. ASH Annual Meeting Abstracts 2012, 120:673.
23. Sexauer A., Perl A., Yang X., Borowitz M., Gocke C., Rajkhowa T., et al. Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML. Blood Nov 15 2012, 120(20):4205-4214.
24. Smith C.C., Wang Q., Chin C.S., Salerno S., Damon L.E., Levis M.J., et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature Apr 15 2012, 485(7397):260-263.
25. Weisberg E., Sattler M., Ray A., Griffin J.D. Drug resistance in mutant FLT3-positive AML. Oncogene 2010, 29(37):5120-5134.
26. Shah N.P., Talpaz M., Deininger M.W., Mauro M.J., Flinn I.W., Bixby D., et al. Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study. Br J Haematol Aug 2013, 162(4):548-552.
27. Smith C.C., Lasater E.A., Zhu X., Lin K.C., Stewart W.K., Damon L.E., et al. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood Apr 18 2013, 121(16):3165-3171.
28. Smith C.C., Perl A.E., Lasater E., Zhang C., Jeschke G., Damon L., et al. PLX3397 is an investigational selective FLT3 inhibitor that retains activity against the clinically-relevant FLT3-ITD/F691L "gatekeeper" mutation in vitro. ASH Annual Meeting Abstracts 2011, 118:764.
29. Smith C.C., Lasater E.A., Lin K.C., Wang Q., McCreery M.Q., Stewart W.K., et al. Crenolanib is a selective type I pan-FLT3 inhibitor. Proc Natl Acad Sci U S A Mar 12 2014, [Epub ahead of print]. 10.1073/pnas.1320661111.
30. Lee H.K., Kim H.W., Lee I.Y., Lee J., Lee J., Jung D.S., et al. G-749, a novel FLT3 kinase inhibitor can overcome drug resistance for the treatment of acute myeloid leukemia. Blood Feb 14 2014, [Epub ahead of print]. 10.1182/blood-2013-04-493916.
31. Fischer T., Stone R.M., Deangelo D.J., Galinsky I., Estey E., Lanza C., et al. Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol Oct 1 2010, 28(28):4339-4345.
32. Williams C.B., Kambhampati S., Fiskus W., Wick J., Dutreix C., Ganguly S., et al. Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia. Pharmacotherapy Dec 2013, 33(12):1341-1352.
33. Barr F.A., Silljé H.H., Nigg E.A. Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol Jun 2004, 5(6):429-440. [Review].
34. Maertens J., Lübbert M., Fiedler W., Fouillard L., Haaland A., Brandwein J.M., et al. Phase I/II study of volasertib (BI 6727), an intravenous Polo-like kinase (Plk) inhibitor, in patients with acute myeloid leukemia (AML): results from the randomized phase II part for volasertib in combination with low-dose cytarabine (LDAC) versus LDAC monotherapy in patients with previously untreated AML ineligible for intensive treatment. Oral presentation at ASH Annual Meeting and Exposition 2012 2012.
35. Ward P.S., Patel J., Wise D.R., Abdel-Wahab O., Bennett B.D., Coller H.A., et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomophic enzymatic activity that converts α-ketoglutarate to 2-hydroxyglutarate. Cancer Cell Mar 2010, 17(3):225-234.
36. Figueroa M.E., Abdel-Wahab O., Lu C., Ward P.S., Patel J., Shih A., et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell Dec 14 2010, 18(6):553-567.
37. Xu W., Yang H., Liu Y., Yang Y., Wang P., Kim S.H., et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell Jan 18 2011, 19(1):17-30.
38. Chaturvedi A., Araujo Cruz M.M., Jyotsana N., Sharma A., Yun H., Görlich K., et al. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood Oct 17 2013, 122(16):2877-2887.
39. Wang F., Travins J., DeLaBarre B., Penard-Lacronique V., Schalm S., Hansen E., et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science May 3 2013, 340(6132):622-626.
40. Stein E., Tallman M., Pollyea D.A., Flinn I.W., Fathi A.T., Stone R.M., et al. Clinical safety and activity in a phase I trial of AG-221, a first in class, potent inhibitor of the IDH2-mutant protein, in patients with IDH2 mutant positive advanced hematologic malignancies. AACR Annual Meeting Abstracts 2014 2014, CT103.
41. Watts J.M., Tallman M.S. Acute promyelocytic leukemia: what is the new standard of care?. Blood Rev Sep 2014, 28(5):205-212.
42. Andreeff M., Jiang S., Zhang X., Konopleva M., Estrov Z., Snell V.E., et al. Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia Nov 1999, 13(11):1881-1892.
43. Schlenk R.F., Fröhling S., Hartmann F., Fischer J.T., Glasmacher A., del Valle F., et al. Phase III study of all-trans retinoic acid in previously untreated patients 61years or older with acute myeloid leukemia. Leukemia Nov 2004, 18(11):1798-1803.
44. Gupta K., Gulen F., Sun L., Aguilera R., Chakrabarti A., Kiselar J., et al. GSK3 is a regulator of RAR-mediated differentiation. Leukemia 2012, 26(6):1277-1285.
45. Tardi P., Johnstone S., Harasym N., Xie S., Harasym T., Zisman N., et al. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res Jan 2009, 33(1):129-139.
46. Feldman E.J., Kolitz J.E., Trang J.M., Liboiron B.D., Swenson C.E., Chiarella M.T., et al. Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia. Leuk Res Oct 2012, 36(10):1283-1289.
47. Lancet J.E., Cortes J.E., Hogge D.E., Tallman M.S., Kovacsovics T.J., Damon L.E., et al. Phase II, multicenter, randomized, open label trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus cytarabine and daunorubicin in patients with untreated AML 60-75years of age. Blood Mar 31 2014, [Epub ahead of print]. 10.1182/blood-2013-12-540971.
48. Liu X.J., Nowak B., Wang Y.Q., Plunkett W. Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks. Chin J Cancer Aug 2012, 31(8):373-380.
49. Kantarjian H., Faderl S., Garcia-Manero G., Luger S., Venugopal P., Maness L., et al. Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. Lancet Oncol Nov 2012, 13(11):1096-1104.
50. O'Brien S., Rizzieri D.A., Vey N., Ravandi F., Krug U.O., Sekeres M.A., et al. Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia. Br J Haematol Sep 2012, 158(5):581-588.
51. Roboz G.J., Rosenblat T., Arellano M., Gobbi M., Altman J.K., Montesinos P., et al. International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia. J Clin Oncol 2014, 32(18):1919-1926.
52. Hoch U., Lynch J., Sato Y., Kashimoto S., Kajikawa F., Furutani Y., et al. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models. Cancer Chemother Pharmacol Jun 2009, 64(1):53-65.
53. Walsby E.J., Coles S.J., Knapper S., Burnett A.K. The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine. Haematologica 2011, 96(3):393-399.
54. Lancet J.E., Ravandi F., Ricklis R.M., Cripe L.D., Kantarjian H.M., Giles F.J., et al. A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia. Leukemia Dec 2011, 25(12):1808-1814.
55. Capizzi R.L., Davis R., Powell B., Cuttner J., Ellison R.R., Cooper M.R., et al. Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia-a cancer and leukemia group B study. J Clin Oncol Mar 1988, 6(3):499-508.
56. Berlier W., Aguera K., El Hamri M., Goutagny M.P., Gallix F., Bertrand Y., et al. l-Asparaginase sensitivity and asparagine synthetase expression in primary tumor cells from AML patients. ASH Annual Meeting Abstracts Dec 2013, 613:1423.
57. Hunault-Berger M., Leguay T., Huguet F., Leprêtre S., Deconinck E., Uribe M.O., et al. Two years follow-up results of Graspall/Graall-SA2-2008 study: l-Asparaginase-loaded red blood cell combined with standard EWALL chemotherapy in older patients with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph-ALL). ASH Annual Meeting Abstracts 2012, 120:1473.
58. Sievers E.L., Larson R.A., Stadtmauer E.A., Estey E., Löwenberg B., Dombret H., et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol Jul 1 2001, 19(13):3244-3254.
59. Petersdorf S.H., Kopecky K.J., Slovak M., Willman C., Nevill T., Brandwein J., et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood Jun 13 2013, 121(24):4854-4860.
60. Burnett A.K., Hills R.K., Milligan D., Kjeldsen L., Kell J., Russell N.H., et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol Feb 1 2011, 29(4):369-377.
61. Burnett A.K., Russell N.H., Hills R.K., Kell J., Freeman S., Kjeldsen L., et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol Nov 10 2012, 30(32):3924-3931.
62. Castaigne S., Pautas C., Terré C., Raffoux E., Bordessoule D., Bastie J.N., et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet Apr 21 2012, 379(9825):1508-1516.
63. Delaunay J., Recher C., Pigneux A., Witz F., Vey N., Blanchet O., et al. Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the GOELAMS AML 2006 IR Study Blood (ASH Annual Meeting Abstracts) 2011, 118:79.
64. Sekeres M.A., Lancet J.E., Wood B.L., Grove L.E., Sandalic L., Sievers E.L., et al. Randomized, phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia. Haematologica Jan 2013, 98(1):119-128.
65. Kung Sutherland M.S., Walter R.B., Jeffrey S.C., Burke P.J., Yu C., Kostner H., et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood Aug 22 2013, 122(8):1455-1463.
66. Walter R.B., Raden B.W., Hong T.C., Flowers D.A., Bernstein I.D., Linenberger M.L. Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. Blood 2003, 102(4):1466-1473.
67. Rosenblat T.L., McDevitt M.R., Mulford D.A., Pandit-Taskar N., Divgi C.R., Panageas K.S., et al. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res Nov 1 2010, 16(21):5303-5311.
68. Jurcic J.G., Rosenblat T.L., McDevitt M.R., Pandit-Taskar N., Carrasquillo J.A., Chanel S.M., et al. Phase I trial of the targeted alpha-particle nano-generator actinium-225 (225Ac-lintuzumab) (anti-CD33; HuM195) in acute myeloid leukemia (AML). J Clin Oncol 2011, 29. [Suppl.; abstr 6516].
69. Roberts A.W., He S., Ritchie D., Hertzberg M.S., Kerridge I., Durrant S.T., et al. A phase I study of anti-CD123 monoclonal antibody (mAb) CSL360 targeting leukemia stem cells (LSC) in AML. J Clin Oncol 2010, 28. [Suppl.; abstr e13012].
70. Pagel J.M., Gooley T.A., Rajendran J., Fisher D.R., Wilson W.A., Sandmaier B.M., et al. Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood Dec 24 2009, 114(27):5444-5453.
71. Majeti R., Chao M.P., Alizadeh A.A., Pang W.W., Jaiswal S., Gibbs K.D., et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell Jul 23 2009, 138(2):286-299.
72. Wang Y.C., Feng L., Yin C.Y., Ma L.N., Wei Y.W., Wang C.M., et al. Effectiveness of anti-CD47 antibody and Ara-C combination targeting therapy NOD/SCID mouse of myeloid leukemia. Zhongguo Dang Dai Er Ke Za Zhi Jul 2013, 15(7):577-582.
73. Topp M.S., Kufer P., Gökbuget N., Goebeler M., Klinger M., Neumann S., et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol Jun 20 2011, 29(18):2493-2498.
74. Bargou R., Leo E., Zugmaier G., Klinger M., Goebeler M., Knop S., et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science Aug 15 2008, 321(5891):974-977.
75. Krupka C., Kufer P., Kischel R., Zugmaier G., Bögeholz J., Köhnke T., et al. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood Jan 16 2014, 123(3):356-365.
76. Laszlo G.S., Gudgeon C.J., Harrington K.H., Dell'Aringa J., Newhall K.J., Means G.D., et al. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood Jan 23 2014, 123(4):554-561.
77. Porter D.L., Collins R.H., Hardy C., Kernan N.A., Drobyski W.R., Giralt S., et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood Feb 15 2000, 95(4):1214-1221.
78. Sadelain M., Brentjens R., Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discovery Apr 2013, 3(4):388-398.
79. Jordan C.T., Upchurch D., Szilvassy S.J., Guzman M.L., Howard D.S., Pettigrew A.L., et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 2000, 14:1777-1784.
80. Du X., Ho M., Pastan I. New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells. J Immunother 2007, 30:607-613.
81. Jin L., Lee E.M., Ramshaw H.S., Busfield S.J., Peoppl A.G., Wilkinson L., et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 2009, 5:31-42.
82. Gill S., Tasian S.K., Ruella M., Shestova O., Li Y., Porter D.L., et al. Efficacy against human acute myeloid leukemia and myeloablation of normal hematopoiesis in a mouse model using chimeric antigen receptor-modified T cells. Blood Mar 4 2014, [Epub ahead of print]. 10.1182/blood-2013-09-529537.
83. Mardiros A., Dos Santos C., McDonald T., Brown C.E., Wang X., Budde L.E., et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood Oct 31 2013, 122(18):3138-3148.
84. Mardiros A., Brown C.E., Budde L.E., Wang X., Forman S.J. Acute myeloid leukemia therapeutics: CARs in the driver's seat. Oncoimmunology Dec 1 2013, 2(12):e27214.
85. Majeti R., Becker M.W., Tian Q., Lee T.L., Yan X., Liu R., et al. Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. Proc Natl Acad Sci U S A Mar 3 2009, 106(9):3396-3401.
86. Saito Y., Kitamura H., Hijikata A., Tomizawa-Murasawa M., Tanaka S., Takagi S., et al. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci Transl Med 2010, 2:17ra9.
87. Gal H., Amariglio N., Trakhtenbrot L., Jacob-Hirsh J., Margalit O., Avigdor A., et al. Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells. Leukemia 2006, 20:2147-2154.
88. Gao L., Bellantuono I., Elsässer A., Marley S.B., Gordon M.Y., Goldman J.M., et al. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000, 95:2198-2203.
89. Van Tendeloo V.F., Van de Velde A., Van Driessche A., Cools N., Anguille S.b., Ladell K., et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci August 3 2009, 107(31):13824-13829. [2010].
90. Keilholz U., Letsch A., Busse A., Asemissen A.M., Bauer S., Blau I.W., et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 2009, 113:6541-6548.
91. Uttenthal B., Martinez-Davila I., Ivey A., Craddock C., Chen F., Virchis A., et al. Wilms' tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses. Br J Haematol Feb 2014, 164(3):366-375.
92. Jabbour E., Daver N., Champlin R., Mathisen M., Oran B., Ciurea S., et al. Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy. Am J Hematol Apr 2014, 89(4):395-398.
93. Lazarus H.M., Litzow M.R., Gale R.P. Improving survival in acute myeloid leukemia: pick the best subjects?. J Clin Oncol Nov 1 2013, 31(31):3854-3856.
94. Gale R.P., Wiernik P.H., Lazarus H.M. Should persons with acute myeloid leukemia have a transplant in first remission?. Leukemia Apr 14 2014, [Epub ahead of print]. 10.1038/leu.2014.129.